Seven alerts, seven double-digit moves

Going for number eight...

August 27, 2025

I’ve been around enough charts to know when something has “repeat offender” energy. This stock has ripped many times this year right after I alerted it, and it’s sitting at a support level right now. No guarantees, of course, but I’m watching it like a hawk today.

TODAY’S TOP ALERT! 

MAIA Biotechnology (NYSE: MAIA)

👉  MAIA is TODAY’S #1 ALERT 👈

Good morning, Folks, Jeff Bishop here.

Wall Street is holding its breath this morning ahead of NVDA’s after-bell earnings drop.

For now, I’m focused on a stock that should be no stranger if you’ve followed my alerts. 

At one point, it was one of my biggest alerts from last year, gaining over 300% from where I first showed it to you.

When I alerted it this January, it ramped as high as 24% that day. Then in March, it peaked at 11% the day I alerted it. 

In May, we saw a 10% intraday gain. That was around the time Zacks Equity Research declared it one of the “Best Momentum Stocks to Buy.”

The stock shot up 17% after my alert in June, and when I alerted it at the start of July, it hit a 13% intraday gain. My late-July alert hit 11% before the close.

Folks, those were seven opportunities to watch double- (or triple!) digit moves.

It’s sitting at a level right now that I think deserves a good, hard look — and I’m not alone in thinking that.

Go to your favorite platform and pull up… 

👉  MAIA is TODAY’S #1 ALERT 👈

You’ll see that it had a huge ramp-up after the trade-war reversal in April. 

From its low on April 10 through early May, it soared an eye-watering 95%.

It has gradually pulled back from that high, but in August, it has traded flat overall but has repeatedly bounced from the $1.45–$1.50 zone (where it’s sitting now).

As long as that floor holds, downside risk is relatively defined.

On the upside, a breakout past $1.75 and then $2.00 could open a retest of the May spike zone near $2.50.

Last week, Diamond Equity Research released an update note on MAIA highlighting “[r]ecent updates [that] further de-risk the THIO program in third-line [non-small cell lung cancer].”

Those updates include this July 28 announcement:

In it, CEO Vlad Vitoc noted that “If we are successful in the Fast Track regulatory pathway, ateganosine could qualify for accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.”

Incorporating the company’s recent financials, Diamond revised its valuation of MAIA to $10.27 per share — 566% higher than yesterday’s closing price.

It’s no secret I really like this stock, and I’m watching it today for a bounce from its support level.

👉 MAIA is TODAY’S #1 ALERT 👈

MAIA is a clinical-stage biopharmaceutical company exploring genuinely groundbreaking cancer treatments.

Here are some highlights you should consider as you do your own homework on the company right now…

1. A Potential Game-Changer in Cancer Treatment

MAIA’s flagship product, THIO (christened "Ateganosine" in March), is a potential game changer in oncology. 

Ateganosine is the only clinical-stage anticancer agent that targets telomeres, which are like protective caps at the ends of chromosomes that cancer cells exploit to keep dividing endlessly. 

Ateganosine breaks down these caps, triggering rapid cancer cell death while activating the immune system to keep fighting even after treatment stops.

This dual-action approach could revolutionize how we think about cancer therapies. Most existing treatments target the immune system or the cancer cells — not both.

MAIA announced in February its plans “to initiate a Phase 3 pivotal trial in 2025, named THIO-104, to evaluate the efficacy of THIO administered in sequence with a checkpoint inhibitor (CPI) in third-line non-small cell lung cancer (NSCLC).”

MAIA’s pipeline

On July 17, MAIA revealed the publication of preclinical data in a leading peer-reviewed journal, Nucleic Acids Research, demonstrating Ateganosine had “a significantly lower 50% inhibitory concentration with superior anticancer efficacy compared with the corresponding monotherapies.”

2. FDA Orphan Drug Designations

In the biotech world,  exclusivity is crucial. MAIA’s Ateganosine has Orphan Drug Designations from the FDA for small cell lung cancer, hepatocellular carcinoma, and glioblastoma. 

This would mean 7 years of market exclusivity post-approval plus tax credits for clinical trial costs.

SCLC alone kills nearly 125,000 people in the U.S. yearly. If MAIA’s drug proves effective, it could dominate a potentially lucrative market.

3. Strong Early Data Is Turning Heads

Updated data from its THIO-101 Phase 2 trial — released on June 5 — are incredibly promising. 

In a heavily pre-treated population, THIO paired with Regeneron’s Libtayo achieved a median overall survival (OS) of 17.8 months — roughly triple the 5 to 6 months for the chemotherapy standard-of-care.

MAIA’s CEO said “this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape.”

Results like these can attract big pharma partnerships and investor interest. Ateganosine is showing real potential to disrupt the market.

And in July, MAIA announced dosing of the first patient in Taiwan, marking the expansion of the trial to Asia and opening “a significantly larger patient pool for its evaluations.”

4. Partnership with Roche 🤝

On June 18, MAIA revealed a clinical master supply agreement with Roche (yes, $257 billion market cap Roche) “for future studies investigating the combination of MAIA’s telomere-targeting agent ateganosine (THIO), sequenced with Roche’s checkpoint inhibitor (CPI), atezolizumab (Tecentriq®), for the treatment of multiple hard-to-treat cancers.”

The two drugs were found to be “highly synergistic” in preclinical studies.

Between this and the Regeneron ($62 billion market cap) partnerships, MAIA’s Ateganosine has attracted attention from some serious pharma heavyweights. 🥊

5. Strong Insider Confidence 💼

Company insiders aren’t just talking, they’re scooping up MAIA shares hand over fist lately:

That’s more than 600,000 shares bought since November alone.

Why It Stands Out:

MAIA isn’t your typical biotech. With a truly novel approach to cancer, strong early data, and heavyweight partnerships, the company could be on the verge of something game-changing. 

Investors looking for exposure to next-gen cancer therapies should do their homework on MAIA immediately, beginning with the company website, as well as the June investor presentation and this March shareholder letter.

As always, be sure to approach your trading in a responsible manner. Trading is very risky, and nothing is ever guaranteed, so never trade with more than you can afford to lose. 

Please read the full disclaimer at the bottom of this email as well so you are aware of additional risks and considerations. Always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: I’ve managed to alert MAIA on six occasions in 2025 when it went on to make double-digit gains the same day. 

It’s at a support level right now that’s been reliable for August, and I think today could be another big one for the stock.

Stay locked into MAIA for all the action!

To Your Success,

Jeff Bishop

Questions or concerns about our products? Contact [email protected] / 1-800-380-7072

DISCLAIMER: This entity is owned by Ragingbull. com, LLC ("RagingBull").  To more fully understand any RB subscription, website, application or other service, please review our full disclaimer located at https://ragingbull.com/disclaimer.

We are disseminating this report on behalf of Sherwood Ventures (SV). Sherwood’s full disclaimer is found here: https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received thirty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on August 27, 2025. Prior to this, we received twenty thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on July 28, 2025. Additionally, we were paid twenty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on July 1, 2025. Before this, we received thirty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on June 18, 2025.  Before this, we received twenty five thousand thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a two day marketing program starting on May 1, 2025. Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on April 23, 2025. Prior to that, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on March 20, 2025.  Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on February 27, 2025. Prior to that, we received thirty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on January 7, 2025, and we also received fifteen thousand dollars (cash) from Legends Media for advertising MAIA Biotechnology, Inc for a one day marketing program on December 16, 2024, and we received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on November 7, 2024, and also twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024 and also fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on November 15  through November 18, 2023, and also fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.